

Supplementary Table 4. Additional Secondary Endpoints in MONARCH

	Adalimumab 40 mg q2w (n=185)	Sarilumab 200 mg q2w (n=184)	P value*
CDAI, week 12			
Mean (SD)	21.1 (14.7)	18.1 (13.1)	0.0465
LS mean change from baseline (SE)	-21.6 (1.0)	-24.9 (1.0)	0.0072
CDAI, week 24			
Mean (SD)	16.6 (10.4)	13.8 (11.4)	0.0244
LS mean change from baseline (SE)	-25.2 (0.8)	-28.9 (0.8)	0.0013
CDAI ≤2.8 (remission), n (%)	5 (2.7)	13 (7.1)	0.0468
CDAI ≤10 (LDA), n (%) [†]	46 (24.9)	77 (41.8)	0.0005
DAS 28-CRP, week 12			
Mean (SD)	4.26 (1.47)	3.51 (1.33)	<0.0001
LS mean change from baseline (SE)	-1.72 (0.099)	-2.48 (0.098)	<0.0001
DAS28-CRP, week 24			
Mean (SD)	3.92 (1.24)	3.07 (1.21)	<0.0001
LS mean change from baseline (SE)	-1.97 (0.09)	-2.86 (0.09)	<0.0001
DAS28-CRP <2.6 (remission), n (%)	25 (13.5)	63 (34.2)	<0.0001
DAS28-CRP ≤3.2 (LDA), n (%)	45 (24.3)	95 (51.6)	<0.0001
ACR components, week 24[‡]			
Tender joint count (0-68)			
Mean (SD)	9.9 (10.6)	9.0 (10.5)	
LS mean change from baseline (SE)	-16.5 (0.8)	-18.2 (0.8)	0.0986
Swollen joint count (0-66)			
Mean (SD)	4.8 (5.6)	4.2 (6.3)	
LS mean change from baseline (SE)	-12.2 (0.5)	-13.4 (0.4)	0.0446
Pain VAS (0-100 mm)			
Mean (SD)	42.5 (23.7)	34.6 (22.5)	
LS mean change from baseline (SE)	-27.4 (1.8)	-36.2 (1.8)	0.0005
Physician global VAS (0-100 mm)			
Mean (SD)	28.0 (18.1)	20.8 (17.1)	
LS mean change from baseline (SE)	-37.8 (1.4)	-45.3 (1.4)	0.0001
Patient global VAS (0-100 mm)			
Mean (SD)	42.5 (22.1)	34.7 (21.6)	
LS mean change from baseline (SE)	-24.8 (1.8)	-33.3 (1.7)	0.0005
HAQ-DI (0-3)			
Mean (SD)	1.2 (0.7)	1.0 (0.7)	
LS mean change from baseline (SE)	-0.43 (0.05)	-0.61 (0.05)	0.0037
CRP (mg/L)			
Mean (SD)	16.7 (25.5)	2.0 (6.6)	
LS mean change from baseline (SE)	-2.91 (1.5)	-17.0 (1.4)	<0.0001

ESR (mm/h)			
Mean (SD)	33.1 (24.8)	13.5 (11.3)	
LS mean change from baseline (SE)	-12.7 (1.4)	-32.1 (1.4)	<0.0001

*Nominal *P* values.

†Post hoc analysis.

‡Lower mean scores indicate less severe disease.

ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28-CRP, 28-joint disease activity score using CRP; DAS28-ESR, DAS28 using erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire–Disability Index; LDA, low disease activity; LS, least squares; q2w, every 2 weeks; SD, standard deviation; SE, standard error. VAS, visual analog scale.